Project Grant R01HL179278
- This federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) aims to support research on modulating the resolution of angiogenesis and normalizing the vasculature for therapeutic benefit in cardiovascular diseases. The $549,665 award, effective January 15, 2025 through November 30, 2028, will fund research conducted by the University of Maryland, Baltimore to investigate mechanisms that regulate the resolution of angiogenesis,...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a $410,449 Project Grant under the Cardiovascular Diseases Research (CFDA 93.837) program to The Leland Stanford Junior University (Stanford University) on August 1, 2025. The funding supports research to develop novel synthetic biology strategies that would enable the quantitative and dynamic regulation of growth factors and cytokines produced from human induced pluripotent stem cell-derived endothelial cells (iPSC-ECs). The goal...
- The University of Rochester was awarded a $226,101 Project Grant from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) to conduct research on pulmonary angioblasts and their role in vascular development. The project aims to leverage existing single-cell RNA sequencing data to uncover novel insights into the cellular characteristics and regulatory mechanisms governing pulmonary angioblasts, which are critical for vascular regeneration and the...
- This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research to define the role of the RNA-binding protein G3BP1 in blood vessel formation. The $147,486 award to Yale University will fund the development of a novel zebrafish model to investigate how G3BP1-mediated post-transcriptional regulation impacts vascular development. The overall objective is to enhance understanding of the gene regulatory networks...
- This Project Grant award, valued at $748,965.00, was provided by the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) to Northwestern University for a research project titled "Vascular Proliferative Resilience - Summary in Adults". The project aims to investigate the dynamics, spatial context, and molecular regulators of endothelial cell proliferation in the aorta, with the goal of deciphering the mechanisms underlying the maintenance of vascular...
- This federal Project Grant award of $740,037, funded by the National Heart Lung and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837), supports research on the regulation of angiogenesis (blood vessel formation) by cardiac fibroblasts following myocardial infarction. The key objectives are to investigate the temporal and spatial expression of pro- and anti-angiogenic factors secreted by cardiac fibroblasts to support cardiac repair and increase vascular...
- The University of Southern California (USC) was awarded a $808,121 Project Grant by the National Heart Lung and Blood Institute under the Cardiovascular Diseases Research federal grant program (CFDA 93.837). The project aims to elucidate how lymphatic endothelial cells detect external fluid forces and convert these signals into a biological program that orchestrates lymphatic valve formation. Specifically, the research will examine the role of the mechanosensitive ion channel PIEZO1 in sensing...
- This Project Grant award of $618,450.00 from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) supports research to identify key regulators of vascular homeostasis and understand how they maintain normal vascular function. The principal investigators at the Medical College of Wisconsin are focusing on understanding the role of the RNA-binding protein PABPC1 in suppressing endothelial cell activation and inflammation to prevent the loss of vascular...
- This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), supports the development of a lesion-targeted nanotherapeutic to address vascular smooth muscle cell (VSMC) dysfunction and mitigate neointimal hyperplasia (NIH), which is a significant issue arising from vascular damage during interventions. The project aims to integrate in vitro transcribed CARMN RNA (a long non-coding RNA critical...
- The federal Project Grant award of $678,803.00 was provided by the National Heart, Lung, and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837) to The Ohio State University. The funding supports research to investigate the role of the mitochondrial deubiquitinase USP30 in regulating microvascular endothelial cell function and its potential as a therapeutic target for acute inflammatory diseases like acute respiratory distress syndrome (ARDS) and sepsis. Key...
This federal Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $790,498 to the University of Southern California (USC) for a research project entitled "Targeting PCBP1 to Ameliorate Pathological Angiogenesis". The grant, which runs from September 1, 2025 to June 30, 2030, aims to investigate the role of the PCBP1 protein and its target AARS2 in regulating vascular endothelial growth factor (VEGF) signaling and neovascularization. The project will utilize unique mouse models with inducible endothelial knockouts of PCBP1 and AARS2 to study their effects on VEGF signaling and blood vessel growth in the context of diseases such as cancer and diabetic retinopathy. The findings from this research are expected to uncover new molecular targets for modulating pathological angiogenesis and advancing the treatment of various human diseases.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $790.5k | 8/30/25 |